We are live on ! Find out more
RNAC icon

Cartesian Therapeutics
RNAC

48 hedge funds and large institutions have $235M invested in Cartesian Therapeutics in 2017 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 3 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 3

90% more capital invested

Capital invested by funds: $124M → $235M (+$111M)

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

29% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 7

4% more funds holding

Funds holding: 46 → 48 (+2)

0.56% more ownership

Funds ownership: 1.56% → 2.12% (+0.56%)

Holders
48
Holders Change
+2
Holders Change %
+4.35%
% of All Funds
1.2%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
9
Increased
27
Reduced
3
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$16.5M
2
GPP
Great Point Partners
Connecticut
+$13.8M
3
PA
Perceptive Advisors
New York
+$9.65M
4
BlackRock
BlackRock
New York
+$4.3M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.04M

Top Sellers

Rank Fund Capital Flow
1
FP
Flagship Pioneering
Massachusetts
-$11.8M
2
UBS Group
UBS Group
Switzerland
-$1.02M
3
Goldman Sachs
Goldman Sachs
New York
-$452K
4
HP
Hikari Power
Japan
-$349K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$192K
Name Holding Trade Value Shares
Change 		Change in
Stake
PVMCV
1
Polaris Venture Management Co V
Massachusetts
$38.2M – – –
O
2
OrbiMed
New York
$36.6M – – –
VC
3
Vivo Capital
California
$22.2M +$16.5M +37,306 New
DM
4
Deerfield Management
New York
$21.1M – – –
GPP
5
Great Point Partners
Connecticut
$18.6M +$13.8M +31,250 New
PA
6
Perceptive Advisors
New York
$15.8M +$9.65M +21,849 +462%
SRF
7
Silver Rock Financial
California
$13.4M – – –
BlackRock
8
BlackRock
New York
$9.94M +$4.3M +9,730 +140%
JP Morgan Chase
9
JP Morgan Chase
New York
$7.13M +$1.69M +3,816 +47%
BBA
10
Baker Bros. Advisors
New York
$5.76M +$1.68M +3,803 +65%
Fidelity Investments
11
Fidelity Investments
Massachusetts
$5.67M – – –
Millennium Management
12
Millennium Management
New York
$5.3M +$436K +986 +12%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$4.73M +$1.27M +2,864 +56%
SFM
14
Sphera Funds Management
Israel
$4.54M – – –
Vanguard Group
15
Vanguard Group
Pennsylvania
$4.32M +$2.04M +4,621 +176%
State Street
16
State Street
Massachusetts
$3.03M +$1.22M +2,755 +118%
CS
17
Candriam SCA
Luxembourg
$2.5M +$1.4M +3,167 +307%
WA
18
Wasatch Advisors
Utah
$2.47M +$731K +1,656 +67%
Northern Trust
19
Northern Trust
Illinois
$2.4M +$1.2M +2,717 +206%
Point72 Asset Management
20
Point72 Asset Management
Connecticut
$2.38M +$1.76M +3,995 New
HLA
21
Hamilton Lane Advisors
Pennsylvania
$1.81M +$240K +544 +22%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$1.21M +$168K +381 +23%
TCIM
23
TIAA CREF Investment Management
New York
$830K +$540K +1,223 +715%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$644K +$260K +589 +120%
BCM
25
Bridgeway Capital Management
Texas
$497K +$368K +833 New
1
2 3

RNAC Hedge Fund Activity: Q2 2017 in Review

48 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q2 2017, worth a combined $235M — up 90% from $124M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new RNAC positions and 7 closed out — a net gain of 2 holders — while 27 added to existing stakes and 3 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $16.5M. The largest seller was Flagship Pioneering, exiting entirely with an estimated $11.8M sold.

  • 48 institutional investors held Cartesian Therapeutics (RNAC) as of Q2 2017, up from 46 in Q1 2017.
  • Funds reported $235M of Cartesian Therapeutics stock for Q2 2017, up 90% quarter-over-quarter.
  • 9 funds opened new Cartesian Therapeutics positions in Q2 2017 and 7 closed out, a net change of +2 holders.
  • The largest Cartesian Therapeutics buyer in Q2 2017 was Vivo Capital, an estimated $16.5M added.
  • The largest Cartesian Therapeutics seller in Q2 2017 was Flagship Pioneering, an estimated $11.8M sold.

Based on aggregated 13F filings for Q2 2017.